11/20/2025 4:44 PM

3 TCRA assumptions

The TCRA plan rests on 3 assumptions.

The first assumption is that if highly motivated the BIG4 are powerful enough to replace their current TLA automation with patented DLA in their clients' clinical labs worldwide and manage the collection of up to $1 trillion of royalty cash flow for TCRA shareholders during the life of the TCRA patents.

The second assumption is that when the BIG4 announce their intention to replace TLA with DLA, the PE firm can immediately raise **$20 billion** for TCRA shareholders at a TCRA company valuation of **$300 billion**; based on investor confidence that the Big 4 can create **$1 trillion** future free cash flow for TCRA.

The third assumption is that as soon as BIG4 understand the TCRA deal structure and their own huge benefits and see that WIRhE will be funded by their actions, they will make their DLA announcements with solid intent to follow up. Thereby, each will instantly own **$86 billion** in future royalty cash flow, PV **$35 billion**.

The 9 TCRA Assumptions

Here is a breakdown of the **key assumptions in the TCRA/WIRhE business plan**, along with an evaluation of **how strong or weak each assumption is** (based on realism, supporting evidence, dependency, and execution complexity):

☑ 1. Wall Street will not look away

There is an opportunity for important Wall Streeters at no cost to themselves to use their influence to prevent **400 Rh babies** from dying every day, and prevent another **100 babies** a day starting their lives with cerebral palsy. This opportunity will also allow them to direct **$365 billion** to non-profits. **They will not look away**.

Funding WIRhE is a pure high finance play. WIRhE is mitigating one of the most important global public health unmet needs. Wall Street high achievers can join a 'club' of influentials formed to promote WIRhE's mission to save 400 Rh babies a day still dying in the developing world. Important Wall Street Figures must be made to realize that their high status in finance is the only force that WIRhE has to get funded. Then, top Wall Street figures will sense a unique responsibility imposed on them to use the power they have to save these babies. **They will not look away**.

Their role will be to make the Big 5 aware of their opportunity to add a significant financial deal to their careers, generate billions in revenue for themselves, greatly improve clinical labs, and contribute **$345 billion** to nonprofits. In particular Big 5

will save 400 babies' lives every day. There is no reputational risk in endorsing the TCRA business plam, but rather great accolades, in teaming up with WIRhE. Dr. Spitalnik, founder of WIRhE is a highly respected professor at Columbia University College of Physicians and Surgeons. They will become financial partners in the Lasker Award winning research at Columbia in the 1960s that eradicated Rh Hemolytic Disease in developed countries. The **$345 billion** that their support will generate will allow them to personally direct billions to their favorite charities. **They will not look away**.

☑ 2. The Clinical Lab Market Will Remain Stable and Grow

The only risk is that people will stop getting sick.

☑ 3. A Major PE Firm Will Lead the Deal

One of the top PE firms, *Apollo, KKR, Blackrock, Blackstone,* will agree to start up and run the TCRA/WIRhE business plan after we give them the idea how to use the patent portfolio. They have huge incentives: saving **140,000** Rh babies lives annually, and making **$80 billion** in profits.

▨ 4. WIRhE will be fully funded when Limited Partners Provide $20B at the single closing event

This depends on the chosen PE firm raising a **$20 billion** fund, a figure that they have raised before.

▨ 5. The Big 4 Will Develop DLA and Compete for Market Share

Their incentive to develop DLA is saving the babies, enormous financial gain, and ensuring survival of their clinical lab automation business.

▨ 6. DLA Technology Proves to be Feasible and Will Be Widely Adopted

TCRA rests on the Big 4 deciding that DLA can greatly improve clinical lab operations, and then declare they will build and market it worldwide.

☑ 7. The TCRA Patent Portfolio Is Strong and Enforceable and Clinical Labs will Pay Royalties

See TCRA Patent Portfolio Spreadsheet.

8. Markets Will Accept TCRA as a Liquid Security

It is well within the power of a top PE firm to create continuing liquidity for TCRA shares by establishing secondary markets and filing for a listing.

9. Regulatory/Legal Risks Will Be Avoided

A DLA license is royalty-free to all manufacturers. The Big 4 will compete separately in a market that any other manufacturer can enter.